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Short‑duration hypothermia 
completed prior to reperfusion 
prevents intracranial pressure 
elevation following ischaemic 
stroke in rats
Daniel Omileke1,2, Sara Azarpeykan1,2, Steven W. Bothwell1,2, Debbie Pepperall1,2, 
Daniel J. Beard1,2, Kirsten Coupland1,2, Adjanie Patabendige1,2,3 & Neil J. Spratt1,2,4*
Reperfusion therapies re‑establish blood flow after arterial occlusion and improve outcome for 
ischaemic stroke patients. Intracranial pressure (ICP) elevation occurs 18–24 h after experimental 
stroke. This elevation is prevented by short‑duration hypothermia spanning the time of reperfusion. 
We aimed to determine whether hypothermia‑rewarming completed prior to reperfusion, also 
prevents ICP elevation 24 h post‑stroke. Transient middle cerebral artery occlusion was performed 
on male outbred Wistar rats. Sixty‑minute hypothermia to 33 °C, followed by rewarming was 
induced prior to reperfusion in one group, and after reperfusion in another group. Normothermia 
controls received identical anaesthesia protocols. ΔICP from pre‑stroke to 24 h post‑stroke was 
measured, and infarct volumes were calculated. Rewarming pre‑reperfusion prevented ICP elevation 
(ΔICP = 0.3 ± 3.9 mmHg vs. normothermia ΔICP = 5.2 ± 2.1 mmHg, p = 0.02) and reduced infarct volume 
(pre‑reperfusion = 78.6 ± 23.7  mm3 vs. normothermia = 125.1 ± 44.3  mm3, p = 0.04) 24 h post‑stroke. 
There were no significant differences in ΔICP or infarct volumes between hypothermia groups 
rewarmed pre‑ or post‑reperfusion. Hypothermia during reperfusion is not necessary for prevention 
of ICP rise or infarct volume reduction. Short‑duration hypothermia may be an applicable early 
treatment strategy for stroke patients prior to‑ during‑, and after reperfusion therapy.
Reperfusion is necessary for the maintenance of tissue integrity in the ischaemic penumbra. Without reperfu-
sion, any neuroprotective treatment measure is unlikely to show efficacy in stroke  patients1. Previous studies by 
our group have demonstrated a dramatic increase in intracranial pressure (ICP) after transient middle cerebral 
artery (MCA) occlusion in  rats2–6. We have also demonstrated that short-duration hypothermia prevents this 
ICP  elevation4–6. However, in studies to date, hypothermia treatment has always spanned the reperfusion phase 
of the transient MCA occlusion model.
Reperfusion marks a time of major activity in the ischaemic brain. Reperfusion after ischaemic stroke is 
defined as the restoration of blood supply to the damaged cerebral tissue. Successful reperfusion significantly 
improves functional outcome in stroke patients and increases the likelihood of disability free  survival7–9. How-
ever, reperfusion therapies carry some risks and in some patients, the rapid restoration of blood flow increases 
the risk of symptomatic intracerebral  haemorrhage10, and may induce secondary damage to the penumbral region 
in what is known as ischaemic-reperfusion injury (R/I)11,12. A main contributing pathological mechanism to R/I 
is the generation of reactive oxygen species (ROS). R/I can become a more serious problem when reperfusion 
therapy is performed outside of the critical time window for treatment. The sudden introduction of blood flow 
into the already compromised ischaemic brain tissue may overwhelm the exhausted endogenous antioxidant 
systems and damaged vascular endothelia, resulting in cerebral oedema and extravasation of blood  cells13. The 
infiltration of leukocytes into the ischaemic brain during reperfusion, as well as the activation of resident micro-
glia are known to play a role in R/I induced inflammation but may also cause further ROS  activation14, thereby 
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creating a vicious cycle of secondary  damage15. Hypothermia has also been shown to be protective against these 
R/I processes described  above16.
Given what we know about hypothermia and ICP elevation, it is possible that cooling during the reperfusion 
phase may be important for ICP rise prevention post-stroke. While hypothermia treatment has been shown to 
reduce infarct volume independent of reperfusion in animal  studies17, these studies did not examine ICP so it is 
unclear whether hypothermia during reperfusion is necessary for prevention of ICP rise. To assess the importance 
of cooling during reperfusion, we aimed to determine whether hypothermia-rewarming completion prior to 
reperfusion onset prevents ICP elevation 24 h following ischaemic stroke, compared to normothermia control 
rats. For direct comparison with our previous work, we included a second hypothermia group that were cooled 
during the reperfusion phase i.e., rewarmed after reperfusion. This group acted as an active comparator, on the 
basis that we have abundant evidence demonstrating the benefits of cooling during the reperfusion phase on 
 ICP4–6. We also aimed to determine whether hypothermia-rewarming pre-reperfusion would reduce infarct 
volume and neurological deficit post-stroke.
Results
A total of 5 animals were excluded from this study. One was excluded due to lack of sufficient drop in perfusion 
units (> 50% drop from baseline in MCA territory) at occlusion (pre-randomisation); 2 were excluded due to 
sudden cessation of breathing after hypothermia initiation (rewarmed pre-reperfusion); 2 due to subarachnoid 
haemorrhage, confirmed at post-mortem (normothermia).
Mean temperature was 32.7 ± 1.6 °C during treatment in the hypothermia groups (n = 12). Mean temperature 
was 37.0 ± 0.6 °C during the equivalent period in the normothermia group (n = 6) (Fig. 1). 
ICP values were 3.58 ± 1.23 mmHg and 3.12 ± 2.52 mmHg at baseline (non-significant), and 3.89 ± 3.50 mmHg 
and 8.34 ± 2.99 mmHg at 24 h (p = 0.03) in the rewarmed pre-reperfusion and normothermia groups, respec-
tively. ∆ICP was significantly lower in the rewarmed pre-reperfusion group versus the normothermia group 
(0.3 ± 3.9 mmHg vs. 5.2 ± 2.1 mmHg, p = 0.02: Fig. 2A). In the rewarmed post-reperfusion group, ICP values were 
4.54 ± 1.56 mmHg at baseline and 3.22 ± 1.59 mmHg at 24 h, which were not significantly different when com-
pared with rewarmed pre-reperfusion ICP. There was no significant difference in ∆ICP between the rewarmed 
pre-reperfusion and rewarmed post-reperfusion groups (0.3 ± 3.9 mmHg vs. − 1.3 ± 2.6 mmHg, p = 0.42: Fig. 2B).
Infarct volume 24 h post-stroke was significantly smaller in the rewarmed pre-reperfusion group versus the 
normothermia group (78.6 ± 23.7  mm3 vs. 125.1 ± 44.3  mm3, p = 0.04: Fig. 3A). There was no significant difference 
in infarct volume between the rewarmed pre-reperfusion and rewarmed post-reperfusion groups (78.6 ± 23.7 
 mm3 vs. 79.5 ± 31.5  mm3, p = 0.55: Fig. 3B). There was no significant difference in oedema volume between the 
rewarmed pre-reperfusion and normothermia groups (6.9 ± 4.9  mm3 vs. 15.2 ± 11.6  mm3, p = 0.14: Fig. 3C). 
Rewarmed pre-reperfusion and rewarmed post-reperfusion data are shown in Fig. 3D. Statistical analysis was 
not performed on this dataset because there was no significant difference between the rewarmed pre-reperfusion 
and normothermia groups (as per our pre-specified analysis plan).
Neurological deficit scores were significantly lower in the rewarmed pre-reperfusion group when compared 
to the normthermia group (1.3 ± 0.5 vs. 4.8 ± 1.0, p = 0.002: Fig. 4A). There was also a significant difference in 
neurological deficit scores amongst the two hypothermia groups. Rewarmed pre-reperfusion animals had lower 
scores compared to the rewarmed post-reperfusion animals (1.3 ± 0.5 vs. 2.8 ± 0.7, p = 0.01: Fig. 4B).
Discussion
In this study, we have shown that 60 min hypothermia to 33 °C with rewarming pre-reperfusion, prevented ICP 
elevation, reduced infarct volume, and reduced neurological deficit 24 h post-stroke compared to normothermia 
controls. We have also shown that there was no significant difference between rewarming before reperfusion and 
rewarming after reperfusion in terms of ICP rise prevention or infarct volume reduction at the same time point.
These results further our understanding of the protective effects of short-duration hypothermia by provid-
ing evidence of cerebroprotection even when hypothermia treatment is completed prior to reperfusion. In all 
our previous studies, reperfusion occurred during the cooling  interval4–6. This was an important timepoint to 
assess as it is necessary to ensure that hypothermia is effective at preventing ICP elevation in reperfused brain. 
Cooling during the reperfusion phase also has clinical relevance as reperfusion therapies are the gold standard 
treatment for ischaemic  stroke18, therefore having a treatment strategy that can be used as an adjunct to reperfu-
sion therapies is advantageous. The results from the present study indicate that hypothermia may be suitable as a 
potential early treatment strategy following a stroke, prior to reperfusion therapy. Here, animals in the rewarmed 
pre-reperfusion group reached target temperature 30 min following occlusion and were only maintained at target 
for 1 h, yet we saw significant ICP rise prevention and infarct volume reduction as were previously reported when 
animals are cooled during the reperfusion  period4,19. This provides evidence that early administration of short-
duration hypothermia may be beneficial to stroke patients, independent of whether it straddles the reperfusion 
interval, in those receiving reperfusion therapies.
Our results also suggest that the earlier onset of cooling may enhance the benefits of hypothermia. Animals 
that were rewarmed pre-reperfusion had significantly lower neurological deficits than animals rewarmed post-
reperfusion. This result is interesting when we consider that infarct volumes did not differ significantly between 
treatment groups, yet functional outcomes did. Functional outcomes more closely align with the clinical situa-
tion, i.e. the modified Rankin  scale20. These results suggest that pre-reperfusion hypothermia-rewarming may 
be of greater benefit to stroke patients in terms of functional outcome. These neurological deficit results could 
likely be explained by the timing of hypothermia initiated in both groups. In order to keep the duration of both 
MCA occlusion and hypothermia identical between groups, hypothermia was initiated 15 min after MCAo in 
the rewarmed pre-reperfusion group but was initiated 75 min after MCAo in the rewarmed post-reperfusion 
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group. Perhaps an earlier treatment strategy in the absence of reperfusion is responsible for better neurological 
 outcome21. It is possible that R/I mechanisms may have advanced too far in reperfused brain for hypothermia to 
elicit its maximal therapeutic benefit. However, interpretation requires a little caution since ICP, and particularly, 
infarct volume , were not significantly different between treatment groups.
We have shown that cooling during reperfusion is not critical for ICP rise prevention post-stroke. This finding 
has important clinical implications. Pre-reperfusion hypothermia has been investigated extensively in the litera-
ture in studies of cardiac injury in  animals22, but also in clinical  investigations23,24. Pre-reperfusion hypothermia 
has also been examined in the context of stroke in animal  studies17,25. Although these studies initiate hypothermia 
prior to reperfusion, the cooling period is maintained long after reperfusion has occurred, therefore these stud-
ies resemble the rewarmed post-reperfusion group in this present study. It is important to note that this study 
utilised very short durations at target temperature. The 60 min at target temperature is half the cooling time of 
previous pre-clinical  investigations4–6, and 1/24th or less of the time of any of the human  studies26. Long dura-
tion hypothermia in clinical trials have reported major logistic and tolerability  issues27–29. The results obtained 
in this study may therefore make a significant difference to our approach to therapeutic hypothermia in stroke 
patients, as hypothermia may only need to be maintained for 60 min to show benefit.
This study demonstrates the previously reported consistency of ICP and infarct data in response to hypother-
mia  treatment19. However, there are a number of limitations that must be noted. First, there was an unavoidable 
Figure 1.  Core body temperature data. (A) rewarmed pre-reperfusion and normothermia. Hypothermia was 
initiated 15 min post-MCAo. After target temperature was reached, hypothermia was maintained for 1 h before 
rewarming, and prior to reperfusion at 2 h post-stroke. (B) rewarmed post-reperfusion and normothermia. 
Hypothermia was initiated 75 min post-MCAo. After target temperature was reached, hypothermia was 
maintained for 1 h before rewarming was initiated. Reperfusion had already occurred at the point of rewarming 
initiation in this group.
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difference in hypothermia start time between the two treatment groups. It was necessary to match the groups for 
ischaemic duration and cooling duration, which therefore meant that cooling onset time could not be matched 
in order to investigate the importance of cooling during reperfusion. Second, this study was not powered for 
behavioural analyses. This study was powered for a primary outcome of change in ICP, not for neurological 
deficit scores, which typically require much larger sample  sizes30. Lastly, we did not assess the deeper molecular 
mechanisms relating to the potential effects of hypothermia treatment on R/I events such as ROS generation or 
inflammation. Such investigations were beyond the scope of this current study, which was focused on exploring 
the importance of reperfusion on ICP elevation. Further work to investigate the molecular mechanisms will be 
necessary to elucidate potential differences between animals rewarmed pre- and post-reperfusion.
In conclusion, our results suggest that very short duration hypothermia-rewarming prior to reperfusion 
should be investigated for potential benefit to stroke patients. Reperfusion status can vary in patients and it 
would therefore be logistically challenging to implement hypothermia during the reperfusion period for all stroke 
patients. The results presented here indicate that therapeutic hypothermia might be a broadly applicable, early 
treatment option in stroke. Pre-reperfusion hypothermia-rewarming could be administered to stroke patients 
in the early acute phase, and irrespective of their reperfusion status at the time of treatment. This may enhance 
the clinical feasibility of therapeutic hypothermia in stroke patients.
Materials and methods
Animals and experimental protocol. Adult male outbred Wistar rats aged 11–12 weeks old (n = 23, Ani-
mal Services Unit, University of Newcastle) weighing 280–320 g were used for this study. Animals were housed 
under standard conditions in a 12 h light–dark cycle with unlimited access to food and water. All experimental 
procedures were in accordance with the Australian code of Practice for the Care and Use of Animals for Sci-
entific Purposes and were approved by the Animal Care and Ethics Committee of the University of Newcastle 
(A-2020-003). This study was reported in accordance with the ARRIVE  guidelines31.
Rats were initially anaesthetised in 5% isoflurane in 50:50  N2:O2 in an induction chamber. Anaesthesia was 
maintained with 2–2.5% isoflurane in the same gas mix and delivered via a custom, low dead space face mask 
with cross flow of gases. Incision sites were shaved, cleaned and injected subcutaneously (s.c.) with 2 mg/kg 
0.05% Bupivacaine (Pfizer, Sydney, Australia). Body temperature was regulated throughout the surgery with a 
rectal temperature thermocouple (RET-2, Physitemp Instruments Inc, Clifton, New Jersey, USA). The femoral 
artery was cannulated with a catheter consisting of 1 and 2 French silicone tubing for continuous monitoring 
of arterial blood pressure and heart rate. Prior to recovery, rectal paracetamol (250 mg/kg, GlaxoSmithKline, 
Brentford, UK) was administered for overnight pain relief. Animals were also injected with saline (2 × 1.5 ml, s.c.) 
to prevent dehydration, and were returned to their cages with free access to softened laboratory chow and water.
Figure 2.  (A) Change in ICP from baseline to 24 h (∆ICP) between rewarmed pre-reperfusion and 
normothermia groups 24 h post-stroke. (B) ∆ICP between rewarmed pre-reperfusion and rewarmed post-
reperfusion hypothermia groups 24 h post-stroke. *p < 0.05. NS not significant.
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Implantation of datalogger device. Datalogger implantation was performed for accurate and con-
tinuous monitoring of core body temperature. Implantation was performed according to previously described 
 methods32. A 2 cm longitudinal incision was made along the right abdominal region, proximal to the right thigh. 
The incision was made deep enough to expose the space at the ventral thigh crease. Haemostats and forceps were 
used to create a pocket under the skin that was large enough to hold the device. The temperature monitoring 
datalogger (Maxim, San Jose, USA) was inserted into the pocket and secured by closing the muscle and skin 
with 4-0 nylon sutures. Temperature measurements were logged every minute over the 24 h period. For analysis, 
5 min recording intervals were chosen.
Figure 3.  Infarct and oedema volume from H&E staining. (A, C) Rewarmed pre-reperfusion and 
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Intracranial pressure and laser Doppler measurement. Cranial surgery was performed according to 
previously described  methods33. To summarise, the ICP probe (OpSens Fibre Optic Pressure Sensors, Canada) 
was inserted epidurally into a saline filled, polyether ether ketone (PEEK) screw (Bregma 2 mm posterior and 
2 mm lateral) in the left parietal bone. Tissue perfusion in the territory supplied by the right middle cerebral 
artery was monitored during middle cerebral artery occlusion (MCAo) and reperfusion using laser Doppler 
flowmetry (LDF). The LDF probe (Moor Instruments, UK) was inserted into a second hollow PEEK screw 
(Bregma 2 mm posterior and 5 mm lateral) in the right parietal bone. For ICP and LDF recordings, the screws 
were secured with dental cement and an airtight seal was created around each probe using a caulking material 
(Silagum, Gunz Dental, Germany). Correct placement of the ICP probe was confirmed by a response to abdomi-
nal compression which was observed on both ICP and arterial blood pressure waveforms. ICP was monitored at 
pre-stroke baseline and again at 24 h post-stroke. To account for minor variation between the baseline ICP of the 
3 experimental groups, change in ICP from baseline to 24 h (∆ICP) was used for all ICP analyses.
Middle cerebral artery occlusion. Transient MCAo was carried out according to our established 
 protocol34,35. To summarise, a 6 cm length of monofilament nylon suture with a silicone tip (3 mm length × 0.38 mm 
O.D silicone) was inserted through the ligated right external carotid artery into the right internal carotid artery. 
The filament was advanced 20 mm through the internal carotid artery, avoiding the pterygopalatine artery, until 
resistance was felt, and a drop in perfusion units (> 50% drop from baseline) on the LDF was observed which 
indicated that the middle cerebral artery has been occluded. At 2 h post-occlusion, reperfusion was achieved by 
retracting the monofilament through the internal carotid artery approximately 18 mm until the silicone tip was 
visible in the external carotid artery stump.
Hypothermia treatment. Immediately after MCAo, animals were randomised by sealed envelope to 
rewarmed pre-reperfusion, rewarmed post-reperfusion or a normothermia group. Target temperature in both 
hypothermia groups was 33  °C and was achieved by the application of fans and ethanol spray using previ-
ously described  methods4,32. In the rewarmed pre-reperfusion group, hypothermia treatment began 15 min after 
MCAo. Once 33 °C was reached, target temperature was maintained for 60 min. At the end of the 60 min cool-
ing period, animals were rewarmed back to 37 °C, before reperfusion had occurred (Fig. 5A). In the rewarmed 
post-reperfusion group, hypothermia treatment began 75  min after MCAo. Once 33  °C was reached, target 
temperature was maintained for 60 min. At the end of the cooling period, animals were rewarmed back to 37 °C. 
In this rewarmed post-reperfusion group, reperfusion had already occurred when animals were being rewarmed 
(Fig. 5B). After treatment or normothermia, animals were placed in a cage half over a warming pad (Passwell, 
South Australia) to aid in thermoregulation and prevent post-operative hypothermia. Animals in the normo-
thermia group were maintained at 37 °C for the duration of the surgery.
Figure 4.  Neurological deficit scores in (A) rewarmed pre-reperfusion and normothermia and (B) rewarmed 
pre-reperfusion and rewarmed post-reperfusion animals. *p < 0.05, **p < 0.01.
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Neurological tests. Prior to post-stroke ICP monitoring at 24 h, animals were tested for stroke-induced 
neurological deficits. The neurological deficit score was composed of the forelimb flexion, torso twist, and lateral 
push tests. Each test was ranked from 0 to 2, and a total score was given out of 6 (higher scores indicated greater 
neurological deficit)36.
Histological analysis and infarct volume measurement. Animals were euthanised 24 h post stroke 
onset. They were transcardially perfused with saline and their brains were removed and sectioned into 6 cor-
onal slices using a rat brain matrix, each of 2  mm thickness. Triphenyltetrazolium chloride (TTC) (Sigma-
Aldrich, Missouri, USA) staining was performed to confirm the presence of ischaemic stroke by identification 
of infarcted tissue (white area). The slices from each brain were incubated for 12 min at 37 °C in 2% TTC. TTC 
was used for early confirmation of infarct, however, these same tissue slices were then fixed, processed, paraffin 
embedded and cut into 5 µm coronal sections for haematoxylin and eosin (H&E) staining. H&E staining was 
used for infarct volume quantification. Images were scanned using a high-resolution scanner (Aperio, Vista, CA, 
USA) and analysed by an investigator blinded to treatment allocation. Infarct (corrected for oedema) was calcu-
lated (Aperio ImageScope) by subtracting the measured interhemispheric volume difference from the measured 
infarct volume for each side. Infarct volumes were corrected for oedema by applying the formula: corrected 
infarct volume  (mm3) = infarct volume × (contralateral volume/ipsilateral volume). Oedema was calculated by 
infarct volume minus corrected infarct  volume5.
Exclusion criteria and statistical analysis. Subarachnoid haemorrhage, equipment malfunction and 
absence of > 50% LDF drop at occlusion were pre-specified exclusion criteria.
A sample size calculation was performed using pilot and previous  data4,5 (G*Power version 3.1) which indi-
cated that 3 animals per group were required to detect a 6 mmHg difference in ∆ICP between the rewarmed 
pre-reperfusion and normothermia groups, with standard settings of alpha 0.05, power 0.8. However, we used 
a minimum sample size of 6 animals per group to allow for outlier effects. Statistical analyses were performed 
using GraphPad Prism version 9.0.1. Data were analysed for normal distribution using the Shapiro–Wilk nor-
mality test. According to the prespecified analysis plan, a primary one-way analysis with two levels (unpaired 
t-test) was conducted to examine if there was a statistical difference between the rewarmed pre-reperfusion and 
normothermia groups using ∆ICP as the primary endpoint. If a significance difference was found, a subsequent 
one-way, two-level analysis was conducted between the rewarmed pre-reperfusion and the rewarmed post-
reperfusion (active comparator) group. The same protocol was used for infarct volume and oedema analyses. 
For non-normally distributed data (neurological deficit scores), the Mann–Whitney U test was conducted using 
Figure 5.  Experimental timeline of hypothermia treatment groups. (A) Shows the timeline for the rewarmed 
pre-reperfusion group, where hypothermia-rewarming is completed prior to reperfusing the rat at 2 h post-
stroke. (B) Shows the timeline for the rewarmed post-reperfusion group, where hypothermia-rewarming is 
completed after reperfusion. ICP intracranial pressure, MCAo middle cerebral artery occlusion, TT target 
temperature, MAP mean arterial blood pressure.
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the same protocol as above. Statistical significance was accepted at p < 0.05. Data are presented as mean ± SD 
unless otherwise stated.
Received: 26 August 2021; Accepted: 1 November 2021
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